A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis
Open Access
- 5 August 2011
- journal article
- research article
- Published by Springer Nature in BMC Neurology
- Vol. 11 (1) , 97
Abstract
Long-term immunosuppression is often required in myasthenia gravis (MG). There are no published trials using methotrexate (MTX) in MG. The steroid-sparing efficacy of azathioprine (AZA) has been demonstrated after 18-months of starting therapy. However, AZA is considered expensive in Africa. We evaluated the steroid-sparing efficacy of MTX (17.5 mg weekly) compared with AZA (2.5 mg/kg daily) in subjects recently diagnosed with generalized MG by assessing their average monthly prednisone requirements.Keywords
This publication has 33 references indexed in Scilit:
- Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literatureAnnals of the Rheumatic Diseases, 2009
- Autoimmune myasthenia gravis: emerging clinical and biological heterogeneityThe Lancet Neurology, 2009
- Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic reviewBritish Journal of Dermatology, 2009
- The MGTX experience: Challenges in planning and executing an international, multicenter clinical trialJournal of Neuroimmunology, 2008
- Optimal use of methotrexate: the advantages of tight controlAnnals of the Rheumatic Diseases, 2007
- Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2003
- Reliability Testing of the Quantitative Myasthenia Gravis ScoreaAnnals of the New York Academy of Sciences, 1998
- METHOTREXATE—THE RELATIONSHIP BETWEEN DOSE AND CLINICAL EFFECTRheumatology, 1993
- Liver histology in rheumatoid arthritis patients receiving long‐term methotrexate therapy. A Prospective Study with Baseline and Sequential Biopsy SamplesArthritis & Rheumatism, 1989
- Preliminary Results of a Double-Blind, Randomized, Placebo-Controlled Trial of Cyclosporine in Myasthenia GravisNew England Journal of Medicine, 1987